Park Hyeongmok, Saravanakumar Gurusamy, Kim Jinseong, Lim Junha, Kim Won Jong
Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.
OmniaMed Co., Ltd, Pohang, 37673, Republic of Korea.
Adv Healthc Mater. 2021 Mar;10(5):e2000834. doi: 10.1002/adhm.202000834. Epub 2020 Oct 19.
The tumor microenvironment (TME), which is composed of cancer cells, stromal cells, immune cells, and extracellular matrices, plays an important role in tumor growth and progression. Thus, targeting the TME using a well-designed nano-drug delivery system is emerging as a promising strategy for the treatment of solid tumors. Compared to normal tissues, the TME presents several distinguishable physiological features such as mildly acidic pH, hypoxia, high level of reactive oxygen species, and overexpression of specific enzymes, that are exploited as stimuli to induce specific changes in the nanocarrier structures, and thereby facilitates target-specific delivery of imaging or chemotherapeutic agents for the early diagnosis or effective treatment, respectively. Recently, smart nanocarriers that respond to more than one stimulus in the TME have also been designed to elicit a more desirable spatiotemporally controlled drug release. This review highlights the recent progress in TME-sensitive nanocarriers designed for more efficient tumor therapy and imaging. In particular, the design strategies, challenges, and critical considerations involved in the fabrication of TME-sensitive nanocarriers, along with their in vitro and in vivo evaluations are discussed.
肿瘤微环境(TME)由癌细胞、基质细胞、免疫细胞和细胞外基质组成,在肿瘤生长和进展中起重要作用。因此,使用精心设计的纳米药物递送系统靶向肿瘤微环境正成为一种有前景的实体肿瘤治疗策略。与正常组织相比,肿瘤微环境呈现出一些可区分的生理特征,如轻度酸性pH值、缺氧、高水平的活性氧和特定酶的过表达,这些特征被用作刺激因素,以诱导纳米载体结构发生特定变化,从而分别促进成像或化疗药物的靶向递送,用于早期诊断或有效治疗。最近,还设计了对肿瘤微环境中多种刺激作出反应的智能纳米载体,以实现更理想的时空控制药物释放。本文综述了为更高效的肿瘤治疗和成像而设计的肿瘤微环境敏感纳米载体的最新进展。特别讨论了肿瘤微环境敏感纳米载体制造过程中涉及的设计策略、挑战和关键考虑因素,以及它们的体外和体内评估。
Adv Healthc Mater. 2021-3
J Nanobiotechnology. 2024-9-28
Adv Drug Deliv Rev. 2021-12
Curr Drug Targets. 2018-2-8
Eur Thyroid J. 2025-7-3
World J Clin Oncol. 2024-7-24
Molecules. 2024-1-4